Mito
Member
- Joined
- Dec 10, 2016
- Messages
- 2,554
A COHORT OF CANCER PATIENTS WITH NO REPORTED CASES OF SARS-COV-2 INFECTION : THE POSSIBLE PREVENTIVE ROLE OF METHYLENE BLUE
Publié par Guérir du Cancer | Mar 28, 2020 | Bleu de Méthylène, Covid-19 | 7 |
Marc Henry1*, Mireille Summa2, Louis Patrick3, Laurent Schwartz4
1 Université de Strasbourg, Chimie Moléculaire du Solide, Institut Le Bel, Strasbourg.
2 Ceremade, Université Paris Dauphine
3 Association Espoir Métabolique
4 Assistance Publique des Hôpitaux de Paris, Paris, France.
Abstract
We report the case of a cohort of 2500 French patients treated among others with methylene blue for cancer care. During the COVID-19 epidemics none of them developed influenza-like illness. Albeit this lack of infection might be by chance alone, it is possible that methylene blue might have a preventive effect for COVID-19 infection. This is in line with the antiviral activity of Chloroquine, a Methylene blue derivative.
Both Chloroquine and Methylene blue have strong antiviral and anti- inflammatory properties probably linked to the change in intracellular pH and redox state.
Conclusion
With the current COVID-19 outbreak, the world is facing a challenge and every possibility of helping people should be considered. Our preliminary data suggest but do not prove that Methylene blue might be a good treatment for influenza- like illnesses. Both Methylene blue and its derivatives such as chloroquine may share similar mechanism of action. Time is ripe for a prospective randomized clinical trial for the treatment of this dreadful disease.
Old drugs which have been tested for other indications ( such as Methylene blue or Chloroquine) have a well-defined safety profile. They are often more effective than new drugs from the High Tech. The Covid 19 epidemics like cancer has a solution. Reporpusing of known molecules will help cure these deadly diseases.
A cohort of cancer patients with no reported cases of SARS-CoV-2 infection : the possible preventive role of Methylene Blue — Guérir du Cancer
Publié par Guérir du Cancer | Mar 28, 2020 | Bleu de Méthylène, Covid-19 | 7 |
Marc Henry1*, Mireille Summa2, Louis Patrick3, Laurent Schwartz4
1 Université de Strasbourg, Chimie Moléculaire du Solide, Institut Le Bel, Strasbourg.
2 Ceremade, Université Paris Dauphine
3 Association Espoir Métabolique
4 Assistance Publique des Hôpitaux de Paris, Paris, France.
Abstract
We report the case of a cohort of 2500 French patients treated among others with methylene blue for cancer care. During the COVID-19 epidemics none of them developed influenza-like illness. Albeit this lack of infection might be by chance alone, it is possible that methylene blue might have a preventive effect for COVID-19 infection. This is in line with the antiviral activity of Chloroquine, a Methylene blue derivative.
Both Chloroquine and Methylene blue have strong antiviral and anti- inflammatory properties probably linked to the change in intracellular pH and redox state.
Conclusion
With the current COVID-19 outbreak, the world is facing a challenge and every possibility of helping people should be considered. Our preliminary data suggest but do not prove that Methylene blue might be a good treatment for influenza- like illnesses. Both Methylene blue and its derivatives such as chloroquine may share similar mechanism of action. Time is ripe for a prospective randomized clinical trial for the treatment of this dreadful disease.
Old drugs which have been tested for other indications ( such as Methylene blue or Chloroquine) have a well-defined safety profile. They are often more effective than new drugs from the High Tech. The Covid 19 epidemics like cancer has a solution. Reporpusing of known molecules will help cure these deadly diseases.
A cohort of cancer patients with no reported cases of SARS-CoV-2 infection : the possible preventive role of Methylene Blue — Guérir du Cancer
Last edited: